IMMVF (Immunovia AB) Total Liabilities: $2.06 Mil (As of Mar. 2026)


IMMVF Immunovia AB IMMVF
44 GF Score
Price $0.02
GF Value $0.01
! 4 Warning Signs
View Full Analysis

What is Immunovia AB Total Liabilities?

Immunovia AB IMMVF -61.59% 44 Total Liabilities is $2.06 Mil as of Mar. 2026. GuruFocus rates IMMVF with a GF Score™ of 44/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review.

Immunovia AB's Total Liabilities for the quarter that ended in Mar. 2026 was $2.06 Mil.

Immunovia AB's quarterly Total Liabilities declined from Sep. 2025 ($4.90 Mil) to Dec. 2025 ($2.52 Mil) and declined from Dec. 2025 ($2.52 Mil) to Mar. 2026 ($2.06 Mil).

Immunovia AB's annual Total Liabilities declined from Dec. 2023 ($3.09 Mil) to Dec. 2024 ($1.95 Mil) but then increased from Dec. 2024 ($1.95 Mil) to Dec. 2025 ($2.52 Mil).

Immunovia AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Immunovia AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovia AB Total Liabilities Chart

Immunovia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.59 5.47 3.09 1.95 2.52

Immunovia AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.43 1.79 4.90 2.52 2.06
IMMVF
44GF Score
Immunovia AB IMMVF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovia AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Immunovia AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.689+(0+0.834
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.52

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=9.492-6.969
=2.52

Immunovia AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.06+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.06

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=7.051-4.991
=2.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.06 Mil mean?
Immunovia AB (IMMVF) has a Total Liabilities of $2.06 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Immunovia AB and its competitors.
Is Immunovia AB's Total Liabilities too high?
Immunovia AB's current Total Liabilities is $2.06 Mil. Overall, Immunovia AB has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Total Liabilities compare to TMO and DHR?
Immunovia AB's Total Liabilities of $2.06 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Immunovia AB and its competitors. Immunovia AB's current Total Liabilities is $2.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Total Liabilities of $2.06 Mil. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Total Liabilities is $2.06 Mil. Immunovia AB's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Total Liabilities is $2.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunovia AB (IMMVF) Overvalued in 2026?

Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued. The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.

Key valuation signals for IMMVF:

  • Total Liabilities: $2.06 Mil
  • GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunovia AB Business Description

Other Exchanges IMMNOV:Sweden0G8X:UK
Address Scheelevagen 8, Medicon Village, Lund, SWE, 223 63
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
44GF Score

Get the complete analysis for IMMVF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price
$0.01
GF Value